Business Wire

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the ...
Business Wire

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

ST. GALLEN, Switzerland & UNIONDALE, N.Y.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results ...
Nasdaq

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Business Insider

Angion Presents Positive Long-term Data from Phase 2 Clinical Trial of ANG-3777 in Delayed Graft Function at the American Society of Nephrology Kidney Week 2019

ANG-3777 shows improved short- and long-term graft function with a positive safety profile in a Phase 2 study New data support company’s ongoing Phase 3 study UNIONDALE, N.Y., Nov. 07, 2019 (GLOBE ...
KTLA

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

-- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a ...
Reuters

Angion Initiates Phase 2 Clinical Trial Of Ang-3777 In Patients With Acute Lung Injury Associated With Covid-19 Pneumonia

* ANGION BIOMEDICA- INITIATED IN BRAZIL PHASE 2 CLINICAL TRIAL OF ANG-3777 IN PATIENTS WITH ACUTE LUNG INJURY ASSOCIATED WITH COVID-19 PNEUMONIA * ANGION SAYS CONDUCTING PHASE 3 REGISTRATION TRIAL OF ...